General MedicationsINJECTIONStandard
TEVIMBRA
islelizumab-jsgr
Standard Dose
10 mg/mL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TEVIMBRA is listed in Drugs@FDA under application 761380 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient islelizumab-jsgr Form and strength INJECTABLE;INJECTION - 10 mg/mL Sponsor BEIGENE Submission history Latest submission status date: 2025-03-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview TEVIMBRA is listed in Drugs@FDA under application 761380 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient islelizumab-jsgr Form and strength INJECTABLE;INJECTION - 10 mg/mL Sponsor BEIGENE Submission history Latest submission status date: 2025-03-03 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.